Patient death triggers a second clinical hold for Curis as FDA seeks more data
After a patient died in a Phase I/IIa clinical trial for leukemia, the FDA has imposed an additional partial hold on Curis’ ongoing Phase I/II lymphoma study with the same drug.
Last week, Curis already paused enrollment for this trial after the FDA put its leukemia trial on partial hold. The holds for these two trials may thwart Curis’ rapid registration goals for the therapy in question, emavusertib, or CA-4948.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.